GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Island Pharmaceuticals Ltd (ASX:ILA) » Definitions » Net Issuance of Debt

Island Pharmaceuticals (ASX:ILA) Net Issuance of Debt : A$0.20 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Island Pharmaceuticals Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Island Pharmaceuticals's net issuance of debt for the six months ended in Dec. 2023 was A$0.31 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.20 Mil.

Island Pharmaceuticals Net Issuance of Debt Historical Data

The historical data trend for Island Pharmaceuticals's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Island Pharmaceuticals Net Issuance of Debt Chart

Island Pharmaceuticals Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Net Issuance of Debt
- - -0.17 0.20

Island Pharmaceuticals Semi-Annual Data
Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Issuance of Debt Get a 7-Day Free Trial - -0.07 -0.10 0.31 -0.11

Island Pharmaceuticals Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Island Pharmaceuticals Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Island Pharmaceuticals's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Island Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Island Pharmaceuticals Ltd (ASX:ILA) » Definitions » Net Issuance of Debt
Comparable Companies
ASX:ATX ASX:NOX ASX:ATH ASX:PTX ASX:RNV ASX:BTC ASX:SPL ASX:NYR ASX:IMC ASX:BIT VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
N/A
Address
c/- Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Website
https://www.islandpharmaceuticals.com
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections. Its drug candidate ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and another mosquito (or vector) borne diseases. The company carries out its research and development activities principally in the geographic regions of Australia and the United States of America.

Island Pharmaceuticals Headlines

No Headlines